Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna

Bone

Volumn 34, Issue 5, 2004, Pages 905-911

  Ward, L M ^a   Rauch, F ^b   White, K E ^c   Filler, G ^a   Matzinger, M A ^a   Letts, M ^a   Travers, R ^b   Econs, M J ^c   Glorieux, F H ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Bone histology; Children; FGF 23; Rickets; Tumour induced osteomalacia

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; BIOCHEMISTRY; BLOOD ANALYSIS; BONE BIOPSY; BONE METABOLISM; BONE MINERAL; BONE RADIOGRAPHY; BONE TUMOR; CANCER SURGERY; CASE REPORT; CHILD; DAILY LIFE ACTIVITY; DISEASE SEVERITY; EXOSTOSIS; FEMALE; GENE SEQUENCE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; ILIAC BONE; METAPHYSIS; ONCOGENIC HYPOPHOSPHATEMIC OSTEOMALACIA; ONSET AGE; OSTEOMALACIA; PEDIATRICS; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SEQUENCE ANALYSIS; ULNA; VITAMIN D RESISTANT RICKETS;

BASE SEQUENCE; BONE NEOPLASMS; CHILD; DNA PRIMERS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA, FAMILIAL; ULNA;

EID: 2342648890     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.12.025     Document Type: Article

References (23)

1. The ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:2000;345-348
2. Aschinberg L.C., Solomon L.M., Zeis P.M., Justice P., Rosenthal I.M. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J. Peds. 91:1977
3. Cai Q., Hodgson S.F., Kao P.C., Lennon V.A., Klee G.G., Zinsmiester A.R., et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N. Engl. J. Med. 330:1994;1645-1649
4. Drezner M. Tumour-induced rickets and osteomalacia. Favus M.J. Primer on the metabolic bone diseases and disorders of mineral metabolism. third ed. 1996;319-325 American Society for Bone and Mineral Research
5. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J. Bone Miner. Res. 7:1992;215-220
6. Econs M.J., Drezner M.K. Tumor-induced osteomalacia - unveiling a new hormone. N. Engl. J. Med. 330:1994;1679-1681
7. Econs M.J., Friedman N.E., Rowe P.S., Speer M.C., Francis F., Strom T.M., et al. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 83:1998;3459-3462
8. Econs M.J., McEnery P.T. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J. Clin. Endocrinol. Metab. 82:1997;674-681
9. Glorieux F.H., Travers R., Taylor A., Bowen J.R., Rauch F., Norman M., Parfitt A.M. Normative data for iliac bone histomorphometry in growing children. Bone. 26:2000;103-109
10. Holm I.A., Huang X., Kunkel L.M. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am. J. Hum. Genet. 60:1997;790-797
11. Hyp-Consortium A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet. 11:1995;130-136
12. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348:2003;1656-1663
13. Kroger H., Vainio P., Nieminen J., Kotaniemi A. Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone. 17:1995;157-159
14. Marie P.J., Glorieux F.H. Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif. Tissue Int. 35:1983;443-448
15. Miyauchi A., Fukase M., Tsutsumi M., Fujita T. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. J. Clin. Endocrinol. Metab. 67:1988;46-53
16. Petersen D.J., Boniface A.M., Schranck F.W., Rupich R.C., Whyte M.P. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J. Bone Miner. Res. 7:1992;583-597
17. Saito H., Kusano K., Kinosaki M., Ito H., Hirata M., Segawa H., et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J. Biol. Chem. 278:2003;2206-2211
18. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6500-6505
19. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 143:2002;3179-3182
20. van der Sluis I.M., de Ridder M.A., Boot A.M., Krenning E.P., de Muinck Keizer-Schrama S.M. Reference data for bone density and body composition measured with dual energy X ray absorptiometry in white children and young adults. Arch. Dis. Child. 87:2002;341-347
21. Whyte M.P., Podgornik M.N., Wollberg V.A., Eddy M.C., McAlister W.H. Pseudo-(tumor-induced) rickets. J. Bone Miner. Res. 16:2001;1564-1571
22. Williams C.J., Rock M., Considine E., McCarron S., Gow P., Ladda R., et al. Three new point mutations in type II procollagen (COL2A1) and identification of a fourth family with the COL2A1 Arg519→Cys base substitution using conformation sensitive gel electrophoresis. Hum. Mol. Genet. 4:1995;309-312
23. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87:2002;4957-4960